RE: Uk pension scheme27 Nov 2025 16:25
We’re in Warwick this week for the PKUK 2025 Technical Meeting – a great opportunity to reflect on where the field is heading as model-informed approaches become increasingly central to modern drug development.
With regulators strengthening expectations around the use of MIDD, and companies under increasing pressure to make 'go/no-go' decisions faster and earlier, there is stronger emphasis on integrating advanced computational models like PBPK and QSP to build robust justification for decisions and, ultimately, improve the chances of success.
🗨️ MIDD is entering a golden age. And over the next few days, we’re looking forward to conversations on where the science is evolving and how quantitative pharmacology will continue to influence future regulatory and development strategies.